Logo image of MRX

MAREX GROUP PLC (MRX) Stock Fundamental Analysis

NASDAQ:MRX - Nasdaq - GB00BMT7GT62 - Common Stock - Currency: USD

48.1  -0.23 (-0.48%)

After market: 48.8 +0.7 (+1.46%)

Fundamental Rating

4

Overall MRX gets a fundamental rating of 4 out of 10. We evaluated MRX against 229 industry peers in the Capital Markets industry. Both the profitability and financial health of MRX have multiple concerns. MRX is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MRX had positive earnings in the past year.
MRX had a positive operating cash flow in the past year.
MRX Yearly Net Income VS EBIT VS OCF VS FCFMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

MRX has a worse Return On Assets (1.24%) than 63.32% of its industry peers.
MRX has a Return On Equity of 30.81%. This is amongst the best in the industry. MRX outperforms 95.63% of its industry peers.
Industry RankSector Rank
ROA 1.24%
ROE 30.81%
ROIC N/A
ROA(3y)0.72%
ROA(5y)N/A
ROE(3y)16.99%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MRX Yearly ROA, ROE, ROICMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 5 10 15 20

1.3 Margins

With a Profit Margin value of 9.43%, MRX is not doing good in the industry: 62.45% of the companies in the same industry are doing better.
MRX's Profit Margin has improved in the last couple of years.
MRX has a Gross Margin of 39.71%. This is in the lower half of the industry: MRX underperforms 65.50% of its industry peers.
MRX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 9.43%
GM 39.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y12.13%
PM growth 5YN/A
GM growth 3Y-15.98%
GM growth 5YN/A
MRX Yearly Profit, Operating, Gross MarginsMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 20 -20 40

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, MRX has more shares outstanding
Compared to 1 year ago, MRX has an improved debt to assets ratio.
MRX Yearly Shares OutstandingMRX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
MRX Yearly Total Debt VS Total AssetsMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

Based on the Altman-Z score of 0.27, we must say that MRX is in the distress zone and has some risk of bankruptcy.
MRX's Altman-Z score of 0.27 is on the low side compared to the rest of the industry. MRX is outperformed by 71.62% of its industry peers.
The Debt to FCF ratio of MRX is 11.19, which is on the high side as it means it would take MRX, 11.19 years of fcf income to pay off all of its debts.
MRX has a Debt to FCF ratio (11.19) which is comparable to the rest of the industry.
A Debt/Equity ratio of 10.92 is on the high side and indicates that MRX has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 10.92, MRX is doing worse than 89.52% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 10.92
Debt/FCF 11.19
Altman-Z 0.27
ROIC/WACCN/A
WACCN/A
MRX Yearly LT Debt VS Equity VS FCFMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 500M 1B 1.5B

2.3 Liquidity

MRX has a Current Ratio of 1.09. This is a normal value and indicates that MRX is financially healthy and should not expect problems in meeting its short term obligations.
MRX's Current ratio of 1.09 is in line compared to the rest of the industry. MRX outperforms 50.66% of its industry peers.
A Quick Ratio of 1.09 indicates that MRX should not have too much problems paying its short term obligations.
MRX has a Quick ratio (1.09) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 1.09
MRX Yearly Current Assets VS Current LiabilitesMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5B 10B 15B 20B

More info and screens

8

3. Growth

3.1 Past

MRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.41%, which is quite impressive.
Measured over the past years, MRX shows a very strong growth in Earnings Per Share. The EPS has been growing by 50.49% on average per year.
Looking at the last year, MRX shows a quite strong growth in Revenue. The Revenue has grown by 19.81% in the last year.
The Revenue has been growing by 36.98% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)39.41%
EPS 3Y50.49%
EPS 5YN/A
EPS Q2Q%50.44%
Revenue 1Y (TTM)19.81%
Revenue growth 3Y36.98%
Revenue growth 5YN/A
Sales Q2Q%-76.39%

3.2 Future

MRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.31% yearly.
Based on estimates for the next years, MRX will show a quite strong growth in Revenue. The Revenue will grow by 10.39% on average per year.
EPS Next Y14.9%
EPS Next 2Y13.06%
EPS Next 3Y12.31%
EPS Next 5YN/A
Revenue Next Year13.86%
Revenue Next 2Y11.03%
Revenue Next 3Y10.39%
Revenue Next 5YN/A

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MRX Yearly Revenue VS EstimatesMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B 2B
MRX Yearly EPS VS EstimatesMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 1 2 3 4

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 12.09, MRX is valued correctly.
Based on the Price/Earnings ratio, MRX is valued a bit cheaper than the industry average as 63.32% of the companies are valued more expensively.
MRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.85.
With a Price/Forward Earnings ratio of 13.92, MRX is valued correctly.
MRX's Price/Forward Earnings ratio is in line with the industry average.
MRX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 20.89, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.09
Fwd PE 13.92
MRX Price Earnings VS Forward Price EarningsMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of MRX indicates a rather cheap valuation: MRX is cheaper than 87.77% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 3
EV/EBITDA N/A
MRX Per share dataMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as MRX's earnings are expected to grow with 12.31% in the coming years.
PEG (NY)0.81
PEG (5Y)N/A
EPS Next 2Y13.06%
EPS Next 3Y12.31%

More info and screens

1

5. Dividend

5.1 Amount

MRX has a Yearly Dividend Yield of 1.19%.
Compared to an average industry Dividend Yield of 8.38, MRX is paying slightly less dividend.
Compared to an average S&P500 Dividend Yield of 2.40, MRX's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 1.19%

5.2 History

MRX has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
MRX Yearly Dividends per shareMRX Yearly Dividends per shareYearly Dividends per share 2024 2025 0.05 0.1 0.15 0.2 0.25

5.3 Sustainability

DPN/A
EPS Next 2Y13.06%
EPS Next 3Y12.31%
MRX Yearly Income VS Free CF VS DividendMRX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

MAREX GROUP PLC

NASDAQ:MRX (5/14/2025, 8:00:02 PM)

After market: 48.8 +0.7 (+1.46%)

48.1

-0.23 (-0.48%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)03-06 2025-03-06/bmo
Earnings (Next)05-15 2025-05-15/bmo
Inst Owners44.65%
Inst Owner Change0%
Ins Owners5.89%
Ins Owner ChangeN/A
Market Cap3.43B
Analysts81.67
Price Target45.14 (-6.15%)
Short Float %3.63%
Short Ratio1.23
Dividend
Industry RankSector Rank
Dividend Yield 1.19%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date03-17 2025-03-17 (0.14)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.61%
Min EPS beat(2)11.13%
Max EPS beat(2)18.1%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.52%
Min Revenue beat(2)2.3%
Max Revenue beat(2)8.73%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.92%
PT rev (3m)17.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)22.32%
EPS NY rev (1m)6.56%
EPS NY rev (3m)12.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)12.98%
Revenue NY rev (1m)0.84%
Revenue NY rev (3m)7.25%
Valuation
Industry RankSector Rank
PE 12.09
Fwd PE 13.92
P/S 1.07
P/FCF 3
P/OCF 2.94
P/B 3.51
P/tB 4.61
EV/EBITDA N/A
EPS(TTM)3.98
EY8.27%
EPS(NY)3.45
Fwd EY7.18%
FCF(TTM)16.06
FCFY33.38%
OCF(TTM)16.33
OCFY33.96%
SpS44.8
BVpS13.71
TBVpS10.44
PEG (NY)0.81
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.24%
ROE 30.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 9.43%
GM 39.71%
FCFM 35.84%
ROA(3y)0.72%
ROA(5y)N/A
ROE(3y)16.99%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y12.13%
PM growth 5YN/A
GM growth 3Y-15.98%
GM growth 5YN/A
F-Score6
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 10.92
Debt/FCF 11.19
Debt/EBITDA N/A
Cap/Depr 69.1%
Cap/Sales 0.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 379.93%
Current Ratio 1.09
Quick Ratio 1.09
Altman-Z 0.27
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)64.15%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.86%
Cap/Sales(5y)N/A
Profit Quality(3y)453.15%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.41%
EPS 3Y50.49%
EPS 5YN/A
EPS Q2Q%50.44%
EPS Next Y14.9%
EPS Next 2Y13.06%
EPS Next 3Y12.31%
EPS Next 5YN/A
Revenue 1Y (TTM)19.81%
Revenue growth 3Y36.98%
Revenue growth 5YN/A
Sales Q2Q%-76.39%
Revenue Next Year13.86%
Revenue Next 2Y11.03%
Revenue Next 3Y10.39%
Revenue Next 5YN/A
EBIT growth 1Y-18.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.29%
EBIT Next 3Y14.38%
EBIT Next 5YN/A
FCF growth 1Y58.2%
FCF growth 3Y35.13%
FCF growth 5YN/A
OCF growth 1Y58.3%
OCF growth 3Y35.2%
OCF growth 5YN/A